EP₁ receptor antagonism mitigates early and late stage renal fibrosis.

ABSTRACT:

Aim

Renal fibrosis is a major driver of chronic kidney disease, yet current treatment strategies are ineffective in attenuating fibrogenesis. The cyclooxygenase/prostaglandin system plays a key role in renal injury and holds great promise as a therapeutic target. Here, we used a translational approach to evaluate the role of the PGE₂ -EP₁ receptor in the pathogenesis of renal fibrosis in several models of kidney injury, including human (fibrotic) kidney slices.

Methods

The anti-fibrotic efficacy of a selective EP₁ receptor antagonist (SC-19220) was studied in mice subjected to unilateral ureteral obstruction (UUO), healthy and fibrotic human precision-cut kidney slices (PCKS), Madin-Darby Canine Kidney (MDCK) cells and primary human renal fib

SUBMITTER: Kresse JC 

PROVIDER: S-EPMC9286353 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature